Bronstein, Gewirtz & Grossman, LLC Announces Class Action Lawsuit against GSK plc
New York, NY – March 17, 2025
Bronstein, Gewirtz & Grossman, LLC, a prominent national law firm, has taken action against GSK plc (“GSK” or “the Company”) (NYSE:GSK) and certain of its officers. The lawsuit alleges that the Company and its executives violated the federal securities laws during the period from February 5, 2020, to August 14, 2022 (the “Class Period”).
Class Definition
The lawsuit seeks to recover damages for all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts (“ADRs”) during the Class Period. Those who wish to participate in this class action are encouraged to contact the law firm before the lead plaintiff deadline.
Allegations against GSK
According to the complaint, GSK and its officers made materially false and misleading statements regarding the Company’s business, operations, and financial condition. Specifically, the lawsuit alleges that GSK failed to disclose material information concerning:
- The Company’s financial performance and prospects
- The impact of regulatory investigations on its business
- The Company’s compliance with applicable laws and regulations
As a result of these alleged false statements, GSK’s stock traded at artificially inflated prices during the Class Period, causing investors harm.
Impact on Individual Investors
If you purchased or otherwise acquired GSK ADRs during the Class Period, you may be able to recover your losses as a member of the proposed class. The lawsuit seeks damages on behalf of the class, and you may be eligible to share in any recovery.
Impact on the World
The consequences of this lawsuit extend beyond the affected investors. GSK’s alleged actions undermine trust in the securities market and the accuracy of public company disclosures. It also highlights the importance of transparency and honesty in corporate communications.
Conclusion
Bronstein, Gewirtz & Grossman, LLC encourages investors who purchased or otherwise acquired GSK ADRs during the Class Period to contact the firm for more information about the class action. The lawsuit seeks to hold GSK and its officers accountable for their alleged misconduct and to recover damages for the affected investors. The case serves as a reminder of the importance of truthful and accurate disclosures in the securities market.
For more information, please contact:
Bronstein, Gewirtz & Grossman, LLC
200 Park Avenue
New York, NY 10166
Phone: 212-697-6484
Fax: 212-736-4841
Email: [email protected]
Attorney Advertising. Prior results do not guarantee a similar outcome.
